Chemotherapeutic implications in microsatellite unstable colorectal cancer

Cancer Biomarkers

Volumn 2, Issue 1-2, 2006, Pages 51-60

  Jo, Won Seok ^a   Carethers, John M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

chemotherapy; colorectal cancer; DNA mismatch repair; microsatellite instability; treatment

Indexed keywords

ANTINEOPLASTIC AGENT; MICROSATELLITE DNA;

COLORECTAL TUMOR; DRUG EFFECT; GENETICS; HUMAN; MICROSATELLITE INSTABILITY; REVIEW;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; HUMANS; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS;

EID: 36448980876     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2006-21-206     Document Type: Article

References (87)

1. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor, E.J. Feuer and M.J. Thun, Cancer statistics, 2005, CA Cancer J Clin 55 (2005), 10-30.
2. J.B. O'Connell, M.A. Maggard and C.Y. Ko, Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging, J Natl Cancer Inst 96 (2004), 1420-1425.
3. R. Gryfe, H. Kim, E.T. Hsieh, M.D. Aronson, E.J. Holowaty, S.B. Bull, M. Redston and S. Gallinger, Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer, N Engl J Med 342 (2000), 69-77.
4. S. Popat, R. Hubner and R.S. Houlston, Systematic review of microsatellite instability and colorectal cancer prognosis, J Clin Oncol 23 (2005), 609-618.
5. J.M. Carethers, E.J. Smith, C.A. Behling, L. Nguyen, A. Tajima, R.T. Doctolero, B.L. Cabrera, A. Goel, C.A. Arnold, K. Miyai ANC C.R. Boland, Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer, Gastroenterology 126 (2004), 394-401.
6. C.M. Ribic, D.J. Sargent, M.J. Moore, S.N. Thibodeau, A.J. French, R.M. Goldberg, S.R. Hamilton, P. Laurent-Puig, R. Gryfe, L.E. Shepherd, D. Tu, M. Redston and S. Gallinger, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med 349 (2003), 247-257.
7. R. Jover, P. Zapater, A. Castells, X. Llor, M. Andreu, J. Cubiella, V. Pinol, R. Xicola, L. Bujanda, J.M. Rene, J. Clofent, X. Bessa, J.D. Morillas, D. Nicolas-Perez, A. Paya and C. Alenda, Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer, Gut (2006), (in press).
8. C.R. Boland, Diagnosis and management of primary and metastatic colorectal cancer, Seminars in Gastrointestinal Disease 3 (1992), 33-45.
9. C.R. Boland, F.A. Sinicrope, D.E. Brenner and J.M. Carethers, Colorectal cancer prevention and treatment, Gastroenterology 118 (2000), S115-S128.
10. J.A. Laurie, C.G. Moertel, T.R. Fleming, H.S. Wieand, J.E. Leigh, J. Rubin, G.W. McCormack, J.B. Gerstner, J.E. Krook, J. Malliard et al., Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic, J Clin Oncol 7 (1989), 1447-1456.
11. C.G. Moertel, T.R. Fleming, J.S. Macdonald, D.G. Haller, J.A. Laurie, P.J. Goodman, J.S. Ungerleider, W.A. Emerson, D.C. Tormey, J.H. Glick et al., Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med 322 (1990), 352-358.
12. C.G. Moertel, T.R. Fleming, J.S. Macdonald, D.G. Haller, J.A. Laurie, C.M. Tangen, J.S. Ungerleider, W.A. Emerson, D.C. Tormey, J.H. Glick, M.H. Veeder and J.A. Mailliard, Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report, Ann Intern Med 122 (1995), 321-326.
13. D.W. Rea, J.W. Nortier, W.W. Ten Bokkel Huinink, S. Falk, D.J. Richel, T. Maughan, G. Groenewegen, J.M. Smit, N. Steven, J.M. Bakker, D. Semiond, D.J. Kerr and C.J. Punt, A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer, Ann Oncol 16 (2005), 1123-1132.
14. Meta-analysis Group in Cancer, Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advance colorectal cancer, J Clin Oncology 16 (1998), 301-308.
15. J.G. Herman, A. Umar, K. Polyak, J.R. Graff, N. Ahuja, J.P. Issa, S. Markowitz, J.K. Willson, S.R. Hamilton, K.W. Kinzler, M.F. Kane, R.D. Kolodner, B. Vogelstein, T.A. Kunkel and S.B. Baylin, Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma, Proc Natl Acad Sci USA 95 (1998), 6870-6875.
16. M.L. Veigl, L. Kasturi, J. Olechnowicz, A.H. Ma, J.D. Lutterbaugh, S. Periyasamy, G.M. Li, J. Drummond, P.L. Modrich, W.D. Sedwick and S.D. Markowitz, Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers, Proc Natl Acad Sci USA 95 (1998), 8698-8702.
17. E.R. Fearon and B. Vogelstein, A genetic model for colorectal tumorigenesis, Cell 61 (1990), 759.
18. A. Goel, C.N. Arnold, D. Niedzwiecki, D.K. Chang, L. Ricciardiello, J.M. Carethers, J.M. Dowell, L.Wasserman C. Compton, R.J. Mayer, M.M. Bertagnolli and C.R. Boland, Characterization of sporadic colon cancer by patterns of genomic instability, Cancer Res 63 (2003), 1608-1614.
19. C.R. Boland, S.N. Thibodeau, S.R. Hamilton, D. Sidransky, J.R. Eshleman, R.W. Burt, S.J. Meltzer, M.A. Rodriguez-Bigas, R. Fodde, G.N. Ranzani and S. Srivastava, A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res 58 (1998), 5248-5257.
20. J.T. Hare and J.H. Taylor, One role for DNA methylation in vertebrate cells is strand discrimination in mismatch repair, Proc Natl Acad Sci USA 82 (1985), 7350-7354.
21. D.C. Thomas, J.D. Roberts and T.A. Kunkel, Heteroduplex repair in extracts of human HeLa cells, J Biol Chem 266 (1990), 3744-3751.
22. S. Acharya, T. Wilson, S. Gradia, M.F. Kane, S. Guerrette, G.T. Marsischky, R. Kolodner and R. Fishel, hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6, Proc Natl Acad Sci USA 93 (1996), 13629-13634.
23. J. Genschel, S.J. Littman, J.T. Drummond and P. Modrich, Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha, J Biol Chem 273 (1998), 19895-19901.
24. F.S. Leach, N.C. Nicolaides, N. Papadopoulos, B. Liu, J. Jen, R. Parsons, P. Peltomaki, P. Sistonen, L.A. Aaltonen, M. Nystrom-Lahti, X.-Y. Guan, J. Zhang, P.S. Meltzer, J.-W. Yu, F.-T. Kao, D.J. Chen, K.M. Cerosaletti, R.E.K. Fournier, S. Todd, T. Lewis, R.J. Leach, S.L. Naylor, J. Weissenbach, J.-P. Mecklin, H. Jarvinen, G.M. Petersen, S.R. Hamilton, J. Green, J. Jass, P. Watson, H.T. Lynch, J.M. Trent, A. de la Chapelle, K.W. Kinzler and B.Volgelstein, Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer, Cell 75 (1993), 1215-1225.
25. R. Fishel, M.K. Lescoe, M.R.S. Rao, N.G. Copeland, N.A. Jenkins, J. Garber and M.R. Kane, The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer, Cell 75 (1993), 1027-1038.
26. N. Papadopoulos, N.C. Nicolaides, Y.-F. Wei, S.M. Ruben, K.C. Carter, C.A. Rosen, W.A. Haseltine, R.D. Fleischmann, C.M. Fraser, M.D. Adams, J.C. Venter, S.R. Hamilton, G.M. Petersen, P. Watson, H.T. Lynch, P. Peltomaki, J.-P. Mecklin, A. de la Chapelle, K.W. Kinzler and B. Volgelstein, Mutation of a mutL homolog in hereditary colon cancer, Science 263 (1994), 1625-1629.
27. C.E. Bronner, S.M. Baker, P.T. Morrison, G. Warren, L.G. Smith, M.K. Lescoe, M. Kane, C. Earabino, J. Lipford, A. Lindblom, P. Tannergard, R.J. Bollag, A.R. Godwin, D.Ward, M. Nordenskjold, R. Fishel, R. Kolodner and R.M. Liskay, Mutation in the DNA mismatch repair homologue hMLH1 is associated with hereditary non-polyposis colon cancer, Nature 368 (1994), 258-261.
28. Y. Akiyama, H. Sato andT.Yamada, Germ-line mutation of the hMSH6/GTBP gene in an atypical HNPCC kindred, Cancer Res 57 (1997), 3920-3923.
29. J. Wijnen, W. de Leeuw, H. Vasen, H. van der Klift, P. Moller, A. Stormorken, H. Meijers-Heijboer, D. Lindhout, F. Menko, S. Vossen, G. Moslein, C. Tops, A. Brocker-Vriends, Y.Wu, R. Hofstra, R. Sijmons, C. Cornelisse, H. Morreau and R. Fodde, Familial endometrial cancer in female carriers of MSH6 germline mutations, Nature Genet 23 (1999), 142-144.
30. R.D. Kolodner, J.D. Tytell, J. Schmeits, M.F. Kane, R. Das Gupta, J. Weger, S. Wahlberg, E.Z. Fox, D. Peel, A. Ziogas, J.E. Garber, S. Syngal, H. Anton-Culver and F.P. Li, Germline msh6 mutations in colorectal cancer families, Cancer Res 59 (1999), 5068-5074.
31. P. Branch, R. Hampson and P. Karran, DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines, Cancer Res 55 (1995), 2304-2309.
32. P. Modrich and R. Lahue, Mismatch repair in replication fidelity, genetic recombination, and cancer biology, Ann Rev Biochem 65 (1996), 101-133.
33. S. Markowitz, J. Wang, L. Myeroff, R. Parsons, L. Sun, J. Lutterbaugh, R.S. Fan, E. Zborowska, K.W. Kinzler, B. Vogelstein, M. Brattain and J.K.V. Willson, Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability, Science 268 (1995), 1336-1338.
34. S. Malkhosyan, N. Rampino, H. Yamamoto and M. Perucho, Frameshift mutator mutations, Nature 382 (1996), 499-500.
35. Y. Mori, J. Yin, A. Rashid, B.A. Leggett, J. Young, L. Simms, P.M. Kuehl, P. Langenberg, S.J. Meltzer and O.C. Stine, Instabilotyping: comprehensive identification of frameshift mutations caused by coding region microsatellite instability, Cancer Res 61 (2001), 6046-6049.
36. N. Rampino, H. Yamamoto, Y. Ionov, Y. Li, H. Sawai, J.C. Reed and M. Perucho, Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype, Science 75 (1997), 967-969.
37. B. Jung, R.T. Doctolero, A. Tajima, A.K. Nguyen, T. Keku, R.S. Sandler and J.M. Carethers, Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers, Gastroenterology 126 (2004), 654-659.
38. J.M. Carethers and T.-T.T. Pham, Mutations of transforming growth factor ?1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines, In Vivo 14 (2000), 13-20.
39. W.M. Grady, A. Rajput, L. Myeroff, D.F. Liu, K. Kwon, J. Willis, and S. Markowitz, Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas, Cancer Res 58 (1998), 3101-3104.
40. B. Jung, E.J. Smith, R.T. Doctolero, P. Gervaz, J.C. Alonso, T. Keku, R.S. Sandler and J.M. Carethers, Influence of target gene mutation on survival, stage, and histology in sporadic microsatellite unstable colon cancers, International Journal of Cancer (2006), (in press).
41. Y. Ionov, M.A. Peinado, S. Malkhosyan et al., Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis, Nature 363 (1993), 558-561.
42. S.N. Thibodeau, G. Bren and D. Schaid, Microsatellite instability in cancer of the proximal colon, Science 260 (1993), 816-819.
43. L.A. Aaltonen, P. Peltomaki, F.S. Leach, P. Sistonen, L. Pylkkanen, J.P. Mecklin, H. Jarvinen, S.M. Powell, J. Jen, S.R. Hamilton, G.M. Petersen, K.W. Kinzler, B. Vogelstein and A. de la Chapelle, Clues to the pathogenesis of familial colorectal cancer, Science 260 (1993), 812-816.
44. T.C. Smyrk, P. Watson, K. Kaul and H.T. Lynch, Tumorinfiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma, Cancer 91 (2001), 2417-2422.
45. J.L. Tsao,Y.Yatabe, R. Salovaara et al., Genetic reconstruction of individual colorectal tumor histories, Proc Natl Acad Sci USA 97 (2000), 1236-1241.
46. M. Guidoboni, R. Gafa, A. Viel, C. Doglioni, A. Russo, A. Santini, L. Del Tin, E. Macri, G. Lanza, M. Boiocchi and R. Dolcetti, Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis, Am J Pathol 159 (2001), 297-304.
47. W.S. Samowitz, K. Curtin, K.N. Ma, D. Schaffer, L.W. Coleman, M. Leppert and M.L. Slattery, Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level, Cancer Epidemiol Biomarkers Prev 10 (2001), 917-923.
48. W. Bodmer, T. Bishop and P. Karran, Genetic steps in colorectal cancer, Nat Genet 6 (1994), 217-219.
49. J.R. Jass, Lymphocytic infiltration and survival in rectal cancer, J Clin Pathol 39 (1986), 585-589.
50. K. Canna, P.A. McArdle, D.C. McMillan, A.M. McNicol, G.W. Smith, R.F. McKee and C.S. McArdle, The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer, Br J Cancer 92 (2005), 651-654.
51. D. Shibata, M.A. Peinado, Y. Ionov, S. Malkhosyan and M. Perucho, Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation, Nat Genet 6 (1994), 273-281.
52. A. Hemminki, J.P. Mecklin, H. Jarvinen, L.A. Aaltonen and H. Joensuu, Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy, Gastroenterology 119 (2000), 921-928.
53. J.R. Lukish, K. Muro, J. DeNobile, R. Katz, J. Williams, D.F. Cruess, W. Drucker, I. Kirsch and S.R. Hamilton, Prognostic significance of DNA replication errors in young patients with colorectal cancer, Ann Surg 227 (1998), 51-56.
54. H. Elsaleh, B. Powell, P. Soontrapornchai, D. Joseph, F. Goria, N. Spry and B. Iacopetta, p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma, Oncology 58 (2000), 52-59.
55. H. Elsaleh, D. Joseph, F. Grieu, N. Zeps, N. Spry and B. Iacopetta, Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer, Lancet 355 (2000), 1745-1750.
56. W.H. de Vos tot Nedervee Cappel, H.J. Neulenbeld, J.H. Keibeuker, F.M. Nagengast, F.H. Menko, G. Griffioen, A. Cats, H. Morreau, H. Gelderblom and H.F. Vasen, Survival after adjuvant 5-FU treatment for stage III coon cancer in hereditary nonpolyposis colorectal cancer, In J Cancer 109 (2004), 468-471.
57. J.M. Carethers, M.T. Hawn, D.P. Chauhan, M.C. Luce, G. Marra, M. Koi and C.R. Boland, Competency in mismatch repair prohibits clonal expansion of cancer cells treated with Nmethyl-N'-nitro-N-nitrosoguanidine, J Clin Invest 98 (1996), 199-206.
58. M.T. Hawn, A. Umar, J.M. Carethers, G. Marra, T.A. Kunkel, C.R. Boland and M. Koi, Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint, Cancer Res 55 (1995), 3721-3725.
59. S. Aebi, B. Kurdi-Haidar, R. Gordon, B. Cenni, H. Zheng, D. Fink, R.D. Christen, C.R. Boland, M. Koi, R. Fishel and S.B. Howell, Loss of DNA mismatch repair in acquired resistance to cisplatin, Cancer Res 56 (1996), 3087-3090.
60. D. Fink, S. Nebel, S. Aebi, H. Zheng, B. Cenni, A. Nehme, R.D. Christen and S.B. Howell, The role of DNA mismatch repair in platinum drug resistance, Cancer Res 56 (1996), 4881-4886.
61. E. Papouli, P. Cejka and J. Jiricny, Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells, Cancer Res 64 (2004), 3391-3394.
62. G.M. Li, DNA mismatch repair and cancer, Front Biosci 8 (2003), 997-1017.
63. R. Magrini, M.R. Bhonde, M.L. Hanski, M. Notter, H. Scherubl, C.R. Boland, M. Zeitz and C. Hanski, Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status, Int J Cancer 101 (2002), 23-31.
64. A. Fedier, V.A. Schwarz, H.Walt, R.D. Carpini, U. Haller and D. Fink, Resistance to topoisomerase poisons due to loss of DNA mismatch repair, Int J Cancer 93 (2001), 571-576.
65. D. Fallik, F. Borrini, V. Boige, J. Viguier, S. Jacob, C. Miquel, J.C. Sabourin, M. Ducreaax and F. Praz, Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer, Cancer Res 63 (2003), 5738-5744.
66. W.B. Parker and Y.C. Cheng, Metabolism and mechanism of action of 5-fluorouracil, Pharmacol Ther 48 (1990), 381-395.
67. P.P. Major, E. Egan, D. Herrick and D.W. Kufe, 5-Fluorouracil incorporation in DNA of human breast carcinoma cells, Cancer Res 42 (1982), 3005-3009.
68. J.M. Carethers, D.P. Chauhan, D. Fink, S. Nebel, R.S. Bresalier, S.B. Howell and C.R. Boland, Mismatch repair proficiency and in vitro response to 5-fluorouracil, Gastroenterology 117 (1999), 123-131.
69. S.J. Caradonna and Y.C. Cheng, The role of deoxyuridine triphosphate nucleotidohydrolase, uracil-DNA glycosylase, and DNA polymerase alpha in the metabolism of FUdR in human tumor cells, Molec Pharmac 18 (1980), 513-520.
70. H.A. Ingraham, B.Y. Tseng and M. Goulian, Mechanism for exclusion of 5-fluorouracil from DNA, Cancer Res 40 (1980), 998-1001.
71. U. Lonn and S. Lonn, DNA lesions in human neoplastic cells and cytotoxicity of 5-fluoropyrimidines, Cancer Res 46 (1986), 3866-3870.
72. W.B. Parker, K.A. Kennedy and P. Klubes, Dissociation of 5-fluorouracil-induced DNA fragmentation from either its incorporation into DNA or its cytotoxicity in murine T-lymphoma (S-49) cells, Cancer Res 47 (1987), 979-982.
73. P.V. Danenberg and A. Lockshin, Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase, Pharmac Ther 13 (1981), 69-90.
74. C.N. Arnold, A. Goel and C.R. Boland, Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines, Int J Cancer 106 (2003), 66-73.
75. A. Tajima, M.T. Hess, B.L. Cabrera, R.D. Kolodner and J.M. Carethers, The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance, Gastroenterology 127 (2004), 1678-1684.
76. M. Meyers, M.W. Wagner, A. Mazurek, C. Schmutte, R. Fishel and D.A. Boothman, DNA mismatch repair-dependent response to fluoropyrimidine-generated damage, J Biol Chem 280 (2005), 5516-5526.
77. L. Stojic, N. Mojas, P. Cejka, M. Di Pietro, S. Ferrari, G. Marra and J. Jiricny, Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase, Genes Dev 18 (2004), 1331-1344.
78. R.S. Tibbetts, K.M. Brumbaugh, J.M.Williams, J.N. Sarkaria, W.A. Cliby, S.Y. Shieh, Y. Taya, C. Prives and R.T. Abraham, A role for ATR in the DNA damage-induced phosphorylation of p53, Genes Dev 13 (1999), 152-157.
79. D.R. Duckett, S.M. Bronstein, Y. Taya and P. Modrich, hMutSalpha-and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage, Proc Natl Acad Sci USA 96 (1999), 12384-12388.
80. M.J. Hickman and L.D. Samson, Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine, Mol Cell 14 (2004), 105-116.
81. A. Nehme, R. Baskaran, S. Aebi, D. Fink, S. Nebel, B. Cenni, J.Y. Wang, S.B. Howell and R.D. Christen, Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and-deficient cells exposed to cisplatin, Cancer Res 57 (1997), 3253-3257.
82. J.G. Gong, A. Costanzo, H.Q. Yang, G. Melino, W.G. Kaelin Jr., M. Levrero and J.Y. Wang, The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage, Nature 399 (1999), 806-809.
83. M. Meyers, M.W. Wagner, H.S. Hwang, T.J. Kinsella and D.A. Boothman, Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses, Cancer Res 61 (2001), 5193-5201.
84. M. Koi, A. Umar, D.P. Chauhan, S.P. Cherian, J.M. Carethers, T.A. Kunkel and C.R. Boland, Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation, Cancer Res 54 (1994), 4308-4312.
85. H.R. Li, E.I. Shagisultanova, K. Yamashita, Z. Piao, M. Perucho and S.R. Malkhosyan, Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin, Cancer Res 64 (2004), 4760-4767.
86. M. Sanada, Y. Takagi, R. Ito and M. Sekiguchi, Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations, DNA Repair 3 (2004), 413-420.
87. K. Pors and L.H. Patterson, DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents, Curr Top Med Chem 5 (2005), 1133-1149.